Extra ‘triple therapy’ drug for type 2 diabetes

NICE has published final guidance recommending dapagliflozin for treating type 2 diabetes in ‘triple therapy’. Dapagliflozin can be added as a third drug where two drugs for type 2 diabetes are not controlling a person’s blood sugar.

 Professor Carole Longson, director of the NICE centre for health technology evaluation, said: “Having a range of drug options makes it easier to tailor treatments for type 2 diabetes to each person’s individual needs. This new guidance recommends dapagliflozin in triple therapy – only in combination with metformin and a sulfonylurea – which will widen the choice available for people whose diabetes isn’t well controlled with two drugs.”

 

 

Other news

Upcoming Events

EBME 2018

Stadium Way West, Milton Keynes, MK1 1ST
26th April 2018

Health GB

Manchester Central Manchester, UK
30 Apr - 2 May 2018

HEALTH+CARE 2018

ExCeL London
27th-28th June 2018

AfPP Residential Conference 2018

University of York
9th - 12th August

Infection Prevention 2018

Scottish Events Campus, Glasgow
30th September - 2nd October 2018

Latest Issue

Clinical Services Journal

Clinical Services Journal

Apr 2018

Patient diagnostics in a heartbeat

Register now to apply for regular copies of Clinical Services Journal and free access to premium content, as well as our regular newsletters.

CSJ Supplements

CSJ Supplements

Aug 2017

Technology with the vision to make surgery better

Register now to apply for regular copies of CSJ Supplements and free access to premium content, as well as our regular newsletters.